Skip to content

CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma

Contrast-enhanced Ultrasound Improves the Diagnostic Performance of Sonographic Risk Stratification System of Thyroid Carcinoma: Comparison Between Integrated Scoring Method and Up-and-down Scoring Method

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06146764
Enrollment
800
Registered
2023-11-27
Start date
2023-03-18
Completion date
2026-07-31
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Carcinoma, Thyroid Nodule

Keywords

Thyroid Nodule, Contrast Media, Gray-scale Ultrasound, Diagnosis, Biopsy

Brief summary

Contrast-enhanced ultrasound (CEUS) can sensitively show the blood perfusion characteristics of thyroid nodules, which is a useful supplement to gray-scale ultrasound. However, there is no standard combined diagnostic method of gray-scale ultrasound and CEUS. Therefore, the aim of this study was to compare the diagnostic performance of the integrated scoring method and the up-and-down scoring method. This study was a multicenter retrospective clinical study and followed the Standards for Reporting of Diagnostic Accuracy Studies (version 2015). Inclusion criteria: 1) participants with at least one thyroid nodule larger than 5 mm confirmed by conventional ultrasound; 2) participants underwent gray-scale ultrasound, contrast-enhanced ultrasound and fine needle aspiration biopsy of the thyroid nodule successively; 3) participants have a final diagnosis of benign or malignant. Exclusion criteria included: 1) participants with cytologic findings of Bethesda I, III, or IV without definitive benign or malignant pathologic findings; 2) participants with a history of thyroid fine needle aspiration, ablation or surgery; 3) participants with low quality ultrasound images (e.g., severe artifacts or low image resolution). According to the American College of Radiology Thyroid Imaging Reporting and Data System, only one thyroid nodule with the highest point was included in each participant. A total of 600 participants from January 2018 to December 2022 were consecutively included in Sun Yat-sen Memorial Hospital of Sun Yat-sen University to form a training set (average age 48 years; Range 24-81 years old). A total of 200 subjects with thyroid nodules from January 2022 to December 2022 were consecutively included to form an external validation set in Houjie Hospital of Dongguan City, Guangdong Province (mean age 46 years; Range 30-74 years). The malignant risk of enrolled thyroid nodules and the necessity of biopsy were evaluated by integrated scoring method and up-and-down scoring method, respectively. The diagnostic performance and unnecessary biopsy rate of the above two methods were calculated and compared.

Interventions

DIAGNOSTIC_TESTContrast-enhanced Ultrasound

Integrated scoring method and up-and-down scoring method

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants with thyroid nodules with a solid component ≥5 mm confirmed by conventional ultrasound; * Participants who underwent conventional ultrasound, contrast-enhanced ultrasound, and fine-needle aspiration biopsy; * Participants with a final benign or malignant pathological results.

Exclusion criteria

* Participants with cytopathology of Bethesda I, III, or IV and without final benign or malignant pathology; * Participants with a history of thyroid ablation or surgery; * Participants with low-quality ultrasound images.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic performanceFirst week after primary completion dateSensitivity, specificity, positive predictive value, negative predictive value, area under the curve
Unnecessary biopsy rateFirst week after primary completion dateThe unnecessary biopsy rate was defined as a percentage of the number of benign nodules among biopsy-indicated nodules in the total nodules.

Countries

China

Contacts

CONTACTJingliang Ruan, Ph.D.
ruanjl3@mail.sysu.edu.cn+8613694202230
CONTACTXiaming Ye, Master
Yexm7@mail.sysu.edu.cn+8613660362226
PRINCIPAL_INVESTIGATORJingliang Ruan, Ph.D.

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

STUDY_DIRECTORBaoming Luo, Professor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026